Skip to main content
TechnologyMay 27, 2026· 2 min read

The new CEO of Remedy admits that Alan Wake and Control sold less than expected

The new CEO of Remedy Entertainment, Jean-Charles Gaudechon, stated that Alan Wake and Control did not achieve the commercial success hoped for by the studio, despite being considered important and well-regarded IPs. The statements came during an interview granted to The Game Business, in which the executive also discussed the future of the Control series and the strategies that Remedy intends to adopt in the coming years.

According to Gaudechon, franchises like Control and Alan Wake still possess great potential and could reach a much wider audience than the current one. The CEO explained that the studio wants to "think bigger" for these intellectual properties, emphasizing how it is a shame that both games did not sell more.

To increase the popularity of the series, Remedy will mainly focus on building a stronger community and transforming the games into multimedia franchises. In this perspective, projects for film adaptations already in the works for both Alan Wake and Control are also included.

The CEO of Remedy also spoke about self-publishing. Gaudechon emphasized the importance of self-publishing, stating that no one can communicate the identity of Remedy's games better than the studio itself. According to the CEO, internally publishing their titles will allow the company to develop a more cohesive communication aligned with the particular and original tone of its productions. This could translate into more unusual and creative marketing campaigns for the upcoming sequel to Control, titled Control: Resonant.

During the interview, there was also discussion about FBC: Firebreak, the shooter published by Remedy in June 2025, which was considered a failure. Gaudechon explained that the experience still allowed the studio to learn a lot about self-publishing, community management, and market positioning of a game.

Finally, the CEO addressed the topic of artificial intelligence. Unlike other large companies in the industry, Remedy is reportedly taking a cautious approach. The studio allows the use of generative AI mainly in the early stages of development and prototyping, while maintaining a careful stance and not fully embracing this technology.